# Study of FP-1039 in Subjects With Endometrial Cancers

> **NCT01244438** · PHASE2 · WITHDRAWN · sponsor: **Five Prime Therapeutics, Inc.**

## Conditions studied

- Endometrial Cancers With FGFR2 Mutations

## Interventions

- **DRUG:** FP-1039

## Key facts

- **NCT ID:** NCT01244438
- **Lead sponsor:** Five Prime Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2011-01
- **Primary completion:** 2012-06
- **Final completion:** 2012-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Study FP1039-002 was not feasible. The original assumption was at least 5% of patients screened would qualify, but after screening 70 patients, none qualified.
- **Last updated:** 2021-12-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01244438

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01244438, "Study of FP-1039 in Subjects With Endometrial Cancers". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01244438. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*